BRIEF-J&J's oral drug to treat inflammation-causing condition in colon meets main goal in mid-stage study
Reuters
Mar 10
BRIEF-J&J's oral drug to treat inflammation-causing condition in colon meets main goal in mid-stage study
March 10 (Reuters) - Johnson & Johnson JNJ.N:
ICOTROKINRA MEETS PRIMARY ENDPOINT OF CLINICAL RESPONSE IN ULCERATIVE COLITIS STUDY AND SHOWS POTENTIAL TO TRANSFORM THE TREATMENT PARADIGM FOR PATIENTS
J&J: ICOTROKINRA WAS WELL TOLERATED
Source text: nPn7xsC0ha
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.